RE:RE:RE:RE:RE:CellPress: Emerging Field of OV Based Cancer ImmunotherapyHypoxia, a condition of insufficient oxygen availability, frequently occurs in solid tumors because of their high oxygen/nutrient demand and abnormal tumor vasculature resulting in a hypoxic TME and stimulation of hypoxia-inducible factor (HIF-1) signaling-in the metastatic cascade.
The systemic administration of ONCY's pelareorep results in the down-regulation of HIF-1 and the conversion of a hypoxic/hostile tumor microenvironment (TME) into one that is conducive for the addition of immune checkpoint inhibitors, like those being combined with pelareorep in the treatment of various solid metastatic tumors, like metastatic pancreatic and breast cancer - as in ONCY's Goblet and Bracelet-1 Phase 2 clinical trials.